Oragenics Activates Three Australian Phase IIa Sites, Holds $6.1 M Cash and Signs LOI
Oragenics has activated three Australian Phase IIa sites for ONP-002, dosing its first concussion patient at Mackay and enrolling at Alfred and Adelaide with zero serious adverse events. The company holds $6.1 million cash and signed an LOI for a complementary CNS medical device licensing agreement.
1. Phase IIa Trial Progress
Oragenics has activated Mackay Base Hospital on March 31, 2026, followed by Alfred Hospital in April and pending activation at Royal Adelaide Hospital, with first patient dosed at Mackay and no serious adverse events recorded. The randomized, placebo-controlled feasibility study targets 40 patients with dosing within 12 hours of concussion and 30-day follow-up neurocognitive testing.
2. Financial Position
As of March 31, 2026, the company held $6.1 million in cash, increased R&D spending 89% to $0.6 million and reduced G&A expenses 4% to $1.6 million. Its active ATM facility provides flexible capital access ahead of clinical and regulatory milestones.
3. Strategic Pipeline Expansion
Oragenics signed a Letter of Intent to license a complementary CNS medical device, carving out TBI indication rights while allowing broader CNS applications. This potential agreement, alongside ONP-002 and AI-identified molecules, could expand the company’s addressable markets and reinforce its CNS platform strategy.